E Merck fuses French orthopaedic units:
This article was originally published in Clinica
E Merck has merged two of its French companies, Prothaid and Impact, to create Merck Biomaterial France. The new company, which hopes to gain 14% of the French orthopaedic market this year, is expected to have an annual turnover of around Fr 160 million ($32.6 million). E Merck acquired Prothaid, specialising in ligament prostheses, last February (see Clinica No 643, p 11) and has now merged it with Impact, which produces joint prostheses. The German company invested Fr 80 million in a manufacturing plant in Valence, while commercial and marketing activities will continue to be carried out in Bordeaux, Levallois and Charnoz.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.